| Literature DB >> 30271785 |
Mladjan Golubovic1, Dragana Stanojevic2, Milan Lazarevic3, Velimir Peric4, Tomislav Kostic2,4, Miodrag Djordjevic5, Sasa Zivic3, Dragan J Milic3,4.
Abstract
INTRODUCTION: The Revised Cardiac Risk Index (RCRI) is an extensively used simple risk stratification tool advocated by the European Society of Cardiology and European Society of Anesthesiology (ESC/ESA).Entities:
Mesh:
Substances:
Year: 2018 PMID: 30271785 PMCID: PMC6151200 DOI: 10.1155/2018/4381527
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographic and clinical characteristics in comparison to the occurrence of cardiovascular complications during the follow-up.
| Parameter | With CV compl. | Without CV compl. |
| ||
|---|---|---|---|---|---|
| Number | % | Number | % | ||
|
| 68.55 ± 6.03 | 66.56 ± 6.59 | 0.1352 | ||
|
| |||||
|
| 26 | 89.7 | 68 | 73.1 | 0.110 |
|
| 3 | 10.3 | 25 | 26.9 | |
|
| 3 | 10.3 | 3 | 3.2 | 0.291 |
|
| 5 | 17.2 | 27 | 29.0 | 0.308 |
|
| 11 | 37.9 | 15 | 16.1 | 0.025 |
|
| 6 | 20.7 | 6 | 6.5 | 0.059 |
|
| 2 | 6.9 | 5 | 5.4 | 1.000 |
|
| 8 | 27.6 | 13 | 14.0 | 0.158 |
|
| 1 | 3.4 | 1 | 1.1 | 0.697 |
|
| 25 | 86.2 | 79 | 84.9 | 1.000 |
|
| 15 | 51.7 | 23 | 24.7 | 0.012 |
|
| 10 | 34.5 | 9 | 9.7 | 0.003 |
|
| 7 | 24.1 | 24 | 25.8 | 1.000 |
|
| 13 | 44.8 | 36 | 38.7 | 0.712 |
|
| 14 | 48.3 | 35 | 37.6 | 0.422 |
|
| |||||
|
| 2 | 6.9 | 6 | 6.5 | 0.3631 |
|
| 4 | 13.8 | 19 | 20.4 | |
|
| 12 | 41.4 | 48 | 51.6 | |
|
| 11 | 37.9 | 20 | 21.5 | |
|
| 2.86 ± 1.53 | 1.69 ± 1.23 | <0.0013 | ||
|
| 25.76 ± 1.96 | 25.89 ± 2.87 | 0.7852 | ||
|
| 2.69 ± 3.22 | 3.46 ± 17.29 | 0.0013 | ||
|
| 862.59 ± 13505.93 | 256.08 ± 575.12 | <0.0013 | ||
|
| 54.14 ± 87.81 | 18.63 ± 17.78 | <0.0013 | ||
|
| 0.00 ± 0.00 | 0.003 ± 0.004 | <0.0013 | ||
† Arithmetic median ± standard deviation, 1Hi-square test, 2T test, 3Mann-Whitney test. Abbreviations. PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; MI: myocardial infarction; DM: diabetes mellitus; ICU: intensive care unit; BMI: body mass index; hsCRP: high sensitivity C-reactive protein; NT pro-BNP: N-terminal brain natriuretic peptide; CK-MB: creatine kinase MB isoform; hsTnI: high sensitivity troponin I.
Drugs in patients with and without CV complications.
| Therapy | with CV complications | Without CV complications | p1 | ||
|---|---|---|---|---|---|
| Broj | % | Broj | % | ||
| Beta blocker | 23 | 79.3 | 67 | 72.0 | 0.593 |
| ACE inhibitors | 24 | 82.8 | 62 | 66.7 | 0.154 |
| Calcium channel blocker | 12 | 41.4 | 18 | 19.8 | 0.036 |
| Antiaggregation therapy | 24 | 82.8 | 55 | 59.1 | 0.036 |
| Statins | 12 | 41.4 | 45 | 48.4 | 0.655 |
| Diuretics | 3 | 10.3 | 6 | 6.5 | 0.769 |
| Long acting nitrates | 2 | 6.9 | 2 | 2.2 | 0.512 |
1Chi-square test.
Predictors of cardiovascular complications: Cox univariate regression analysis.
|
|
|
|
|
|---|---|---|---|
|
| 1.039 | 0.980-1.101 | 0.201 |
|
| 2.811 | 0.851-9.290 | 0.090 |
|
| 2.388 | 0.721-7.906 | 0.154 |
|
| 1.052 | 0.366-3.024 | 0.924 |
|
| 2.490 | 1.201-5.160 | 0.014 |
|
| 0.918 | 0.392-2.150 | 0.845 |
|
| 1.290 | 0.620-2.682 | 0.496 |
|
| 1.531 | 0.739-3.172 | 0.252 |
|
| 0.988 | 0.864-1.130 | 0.864 |
|
| 1.179 | 1.098-1.266 | <0.001 |
|
| 1.020 | 0.882-1.180 | 0.789 |
|
| 1.032 | 1.015-1.050 | <0.001 |
|
| 1.193 | 1.062-1.339 | 0.003 |
|
| 1.412 | 0.931-2.139 | 0.104 |
|
| 1.668 | 1.318-2.111 | <0.001 |
|
| 0.997 | 0.971-1.024 | 0.833 |
|
| 1.006 | 1.002-1.009 | 0.001 |
|
| 5.482 | 2.953-10.176 | <0.001 |
|
| |||
|
| 9.661 | 4.386-21.332 | <0.001 |
OR: odds ratio, 95% CI: 95% confidential interval. Abbreviations. CVD: cardiovascular disease; BMI: Body Mass Index; V-POSSUM: Vascular Physiological and Operative Severity Score for the enumeration of Mortality and Morbidity; RCRI: Revised Cardiac Risk Index; ICU: Intensive Care Unit; hsCRP: high sensitivity C-reactive protein; NT pro-BNP: N-terminal brain natriuretic peptide; CK-MB: creatine kinase MB isoform; hsTnI: high sensitivity troponin I.
Discriminative ability of different biomarker combinations.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
| ΔAUC | p-value1 | |||||
|
| RCRI+V-POSSUM | 0.702 | 0.057 | 0.590-0,814 | 0,261 | <0,001 |
|
| RCRI+NT pro-BNP+V-POSSUM | 0.815 | 0.049 | 0.718-0,912 | 0,148 | 0,003 |
|
| RCRI+NT pro-BNP | 0.830 | 0.049 | 0.733-0,927 | 0.133 | 0.010 |
|
| RCRI+hsTnI | 0.909 | 0.027 | 0.856-0,961 | 0.055 | 0.003 |
|
| RCRI+hsTnI+NT pro-BNP | 0.945 | 0.019 | 0.907-0,982 | 0,017 | 0,035 |
|
| RCRI+hsTnI+V-POSSUM | 0.955 | 0.017 | 0.922-0,988 | 0.008 | 0.044 |
|
| RCRI+NT pro-BNP+V-POSSUM+hsTnI | 0.963 | 0.014 | 0.935-0,992 | - | |
Abbreviations. V-POSSUM: Vascular Physiological and Operative Severity Score for the enumeration of Mortality and Morbidity; RCRI: Revised Cardiac Risk Index; hsCRP: high sensitivity C-reactive protein; NT pro-BNP: N-terminal brain natriuretic peptide; hsTnI: high sensitivity troponin I, Se: sensitivity, AUC: area under curve, and 1DeLong test.
NRI and IDI for combined markers.
| Combination of biomarkers | NRI | 95% CI | p | IDI | 95% CI | p |
|---|---|---|---|---|---|---|
|
| referent group | |||||
|
| 1.222 | 0.951-1.493 | <0.001 | 0.229 | 0.115-0.463 | 0.002 |
|
| 0.222 | -0.795-1.239 | 0.668 | 0.048 | -0.143-0.239 | 0.690 |
|
| 0.222 | -0.795-1.239 | 0.668 | 0.032 | -0.132-0.203 | 0.714 |
|
| -0.278 | -1.169-0.613 | 0.541 | 0.013 | -0.102-0.127 | 0.827 |
|
| -0.222 | -1.328-0.884 | 0.693 | 0.031 | -0.143-0.206 | 0.724 |
|
| 0.778 | 0.264-1.291 | 0.003 | 0.289 | 0.115-0.463 | 0.002 |
|
| 0.783 | 0.254-1.301 | 0.003 | 0.290 | 0.117-0.470 | 0.001 |
NRI: net reclassification index, IDI: integrated discrimination index. Abbreviations. CVD: cardiovascular disease; BMI: Body Mass Index; V-POSSUM: Vascular Physiological and Operative Severity Score for the enumeration of Mortality and Morbidity; RCRI: Revised Cardiac Risk Index; ICU: Intensive Care Unit; hsCRP: high sensitivity C-reactive protein; NT pro-BNP: N-terminal brain natriuretic peptide; CK-MB: creatine kinase MB isoform; hsTnI: high sensitivity troponin I.
Figure 1RCRI: Revised Cardiac Risk Index; NT pro-BNP: N-terminal pro b-type natriuretic peptide; hs TnI: high-sensitivity troponin I; V-POSSUM: Vascular Physiological and Operative Severity Score to enumerate the mortality and morbidity; ROC: Receiver Operating Characteristic.